Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Drug Profile

Anti-CEA-CAR-T-cell-therapy-TNK-Therapeutics

Alternative Names: Anti-CEA CAR-T; Anti-CEA T-cells; CAR-T CEA; CAR-T-CEA-therapy; CEA CART; Designer T-cells

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BDL Products, Inc.; CARgenix Holdings LLC
  • Developer Roger Williams Medical Center
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Liver metastases

Most Recent Events

  • 03 Apr 2018 Phase-I development is ongoing in Liver metastases(Inoperable/Unresectable, Second-line therapy or greater) in USA (Intrahepatic, Infusion)
  • 05 Mar 2018 Initial efficacy and adverse events data from a phase Ib HITM-SURE trial in Liver metastases released by Sorrento Therapeutics
  • 05 Mar 2018 Sorrento Therapeutics plans a clinical trial for Cancer (Combination therapy) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top